Antecedent infections, recent developments and future directions in Guillain-Barré syndrome

Authors

  • Rashid Iqbal Department of Medical Technology, Shifa college of Medical Technology, Shifa Tameer-e Millat University, Islamabad, Pakistan
  • Muhammad Javaid Asad Department of Biochemistry, University Institute of Biochemistry and Biotechnology, Pir Mehr Ali Shah, Arid Agriculture University, Rawalpindi, Pakistan
  • Raja Tahir Mahmood Department of Biotechnology, Mirpur University of Science and Technology, Mirpur, Azad Jammu and Kashmir, Pakistan
  • Muhammad Basir Shah Department of Biotechnology, University Institute of Biochemistry and Biotechnology, Pir Mehr Ali Shah, Arid Agriculture University, Rawalpindi, Pakistan
  • Zahida Nawaz Department of Plant Breeding and Genetics, Pir Mehr Ali Shah, Arid Agriculture University, Rawalpindi, Pakistan
  • Saima Siddiqi Department of Biomedical and Genetic Engineering, KRL Hospital, Islamabad, Pakistan

DOI:

https://doi.org/10.47391/JPMA.5369

Abstract

The Guillain-Barré syndrome is an autoimmune polyradiculoneuropathy causing symmetrical weakness of limbs. After poliomyelitis, it is the second most common cause of paralysis, with an annual incidence of 0.84-1.91 per 100,000 individuals. The syndrome affects both men and women, showing a male preponderance. Campylobacter jejuni, epstein-barr virus, cytomegalovirus, mycoplasma pneumoniae and hemophilus influenzae are amongst the most common causative agents of Guillain-Barré syndrome. Several immunological and genetic factors have been recognised as the risk factors. Human leukocyte antigen, cluster of differentiation 1, and tumor necrosis factor-alpha alleles are among the frequently investigated loci in Guillain-Barré syndrome. Genome-wide association studies have found no significant association of Guillain-Barré syndrome with common variants. Many vaccines against Campylobacter jejuni infection have been proposed, but there are concerns about the efficacy and safety of these vaccines. So far, there is no approved vaccine against Campylobacter jejuni.

Published

2022-12-15

Issue

Section

Narrative Review